Abstract

Key Points The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence supporting the use of transcatheter tricuspid valve interventions for treating severe tricuspid regurgitation in high‐risk surgical patients. In the highly anticipated CLASP II TR pivotal trial (NCT04097145), patients will be randomized to receive treatment with the PASCAL system and optimal medical therapy or optimal medical therapy alone.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.